Quantcast

Latest biopharmaceutical Stories

2014-05-28 04:24:21

LONDON and TORONTO, May 28, 2014 /PRNewswire/ -- ThioBridge(TM) linker to attach cytotoxic payloads to alpha fetoprotein PolyTherics Limited ("PolyTherics"), an Abzena company that provides technologies and services to enable the development of better biopharmaceuticals, today announced a collaboration with Alpha Cancer Technologies Inc. ("ACT"), a Canadian company with a targeted drug delivery platform based on alpha fetoprotein ("AFP"). PolyTherics will produce...

2014-05-23 04:20:53

LONDON, May 23, 2014 /PRNewswire/ -- New Company Created to be a Leading Provider of Technologies and Services to Enable Better Biopharmaceuticals - PolyTherics and Antitope to continue to trade as wholly owned subsidiaries of Abzena - New brand highlights depth and range of offering to the global biopharmaceutical industry - Abzena to establish headquarters in Cambridge, UK PolyTherics Limited ("PolyTherics"), a...

2014-05-22 20:22:50

Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced the issuing of Patent No. 8,722,964 entitled, "Genetically Engineered or Transgenic Rats Exhibiting a Cancer Phenotype Due to a Disruption of Germline Tumor Suppressor Genes" on May 13th. LEXINGTON, Ky., May 22, 2014 /PRNewswire-iReach/ -- Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced the issuing of Patent No. 8,722,964 entitled, "Genetically Engineered or Transgenic Rats...

2014-05-22 08:29:44

MONROVIA, Calif., May 22, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014 at 8:00 a.m. EDT in New York City, NY. A live audio webcast of the...

2014-05-21 23:14:04

Reliable Biopharmaceutical Corporation in partnership with Wilshire Technologies has launched Phytochol®, a vegetal-derived, semi-synthetic cGMP Cholesterol for the Biopharmaceutical market. St. Louis, Missouri (PRWEB) May 21, 2014 The pharmaceutical industry is poised to enter a new paradigm in drug manufacture. Firmly grounded in biotechnology, protein-based pharmaceuticals offer the promise of achieving drug benefits far beyond anything yet accomplished by small molecule drugs....

2014-05-20 12:34:14

DUBLIN, May 20, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/9trl4k/11th_annual) has announced the addition of the "11th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 The 11th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production from BioPlan Associates, Inc., a global analysis of 238 biomanufacturers and...

2014-05-20 08:33:12

SUNNYVALE, Calif., May 20, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) is pleased to announce that Gregory R. Wade has joined the company as Executive Vice President of Business Development. In his position, Greg will further establish the Business Development department and lead all Business Development and Competitive Intelligence efforts. Greg is a biopharmaceutical industry veteran with over 20 years of experience and previously held leadership...

2014-05-19 08:28:15

HERZLIYA, Israel, May 19, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced the appointment of consultants Lee S. Simon, MD, FACP, FACR and David Isenberg, MD, for the planned Phase II trial for the Company's hCDR1 compound for the treatment of...

2014-05-16 08:25:52

CAMBRIDGE, England, May 16, 2014 /PRNewswire/ -- Series B Financing includes the Wellcome Trust and the Bill & Melinda Gates Foundation Kymab, a monoclonal antibody biopharmaceutical company, announced today it has successfully raised US$40 million in a Series B financing. The Bill & Melinda Gates Foundation joins existing investor, the Wellcome Trust, each investing US$20 million. The funds will enable Kymab to maximise the potential of its Kymouse(TM)...

2014-05-15 16:28:55

TEL AVIV, Israel, May 15, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, reported its financial results for the quarter ended March 31, 2014. These results are discussed in Galmed's Form 6-K filed with the U.S. Securities and Exchange Commission (the "SEC") on May 14, 2014,...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related